Table 1 Characteristics of malignant glioma cell line reported in 212 included studies
Characteristics | Overall N = 212 | Year of publication | ||
|---|---|---|---|---|
Before 2015 N = 72 | 2015-2017 N = 63 | 2018 or after N = 77 | ||
Type of cell line | ||||
Human glioma cell line(s) | 193 (91.1%) | 65 (90.3%) | 57 (90.5%) | 71 (92.2%) |
Murine glioma cell line(s) | 23 (10.8%) | 5 (6.9%) | 6 (9.5%) | 12 (15.4%) |
Patient-derived cell line(s) | 22 (10.4%) | 9 (12.5%) | 7 (11.1%) | 6 (7.7%) |
Number of cell lines used | ||||
One | 48 (22.6%) | 14 (19.4%) | 15 (23.8%) | 19 (24.7%) |
Two | 74 (34.9%) | 19 (26.4%) | 26 (41.3%) | 29 (37.7%) |
Three or more | 90 (42.5%) | 39 (54.2%) | 22 (34.9%) | 29 (37.7%) |
Ten commonest cell lines | ||||
U87 | 129 (60.4%) | 47 (65.3%) | 37 (58.7%) | 44 (57.1%) |
U251 | 87 (41.0%) | 24 (33.3%) | 31 (49.2%) | 33 (41.6%) |
T98G | 56 (26.4%) | 25 (34.7%) | 11 (17.5%) | 20 (26.0%) |
A172 | 29 (13.7%) | 8 (11.1%) | 11 (17.5%) | 10 (13.0%) |
U373 | 27 (12.7%) | 15 (20.8%) | 6 (9.5%) | 6 (7.8%) |
U138 | 26 (12.3%) | 15 (20.8%) | 6 (9.5%) | 5 (6.5%) |
LN229 | 22 (10.4%) | 7 (9.7%) | 4 (6.3%) | 11 (14.3%) |
C6 | 20 (9.4%) | 5 (6.9%) | 6 (9.5%) | 9 (11.7%) |
LN18 | 13 (6.6%) | 6 (8.3%) | 2 (3.2%) | 5 (6.5%) |
U118 | 14 (6.6%) | 5 (6.9%) | 5 (7.9%) | 4 (5.2%) |